ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Apigenin 7-glucoside reprograms tumor metabolism and enhances immunotherapy efficacy in colorectal cancer via DLX5.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe progression of colorectal cancer (CRC) is closely associated with glycolysis, angiogenesis and immune response. While the natural flavonoid Apigenin 7-glucoside (A7G) exhibits anti-tumor potential, its effects on these three processes remain unclear. This study aims to investigate the impact of A7G on the CRC landscape and to assess its synergistic effect when combined with PD-1 inhibitors.
methodsWestern blotting was used to detect the effect of A7G on glycolysis and angiogenesis-related factors. Immunohistochemistry and flow cytometry were employed to analyze changes in the tumor immune microenvironment. The CT26 mouse xenograft model with overexpressed DLX5 was established to evaluate the role of A7G in modulating metabolic and immune responses. Finally, the therapeutic effect of A7G in combination with PD-1 inhibitors was explored.
resultsA7G significantly decreased the expression of glycolysis and angiogenesis-related factors, a process partially reversed by DLX5 overexpression. Flow cytometry analysis showed that A7G treatment increased the ratio of CD4⁺ T cells/CD8⁺ T cells and reduced the infiltration of M2 macrophages and Treg cells, which was also modulated by DLX5. When combined with PD-1 inhibitors, A7G markedly suppressed tumor growth and enhanced the efficacy of immune therapy.
conclusionA7G treatment demonstrated potential anti-tumor activity in CRC, which is characterized by the simultaneous attenuation of glycolysis and immune evasion via the DLX5 axis. When used in combination with PD-1 inhibitors, A7G significantly enhances the effects of immunotherapy, providing a novel strategy for cancer treatment.
Indexed as
Identifiers
41739401What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.